Alvotech On The Verge Of New Chapter As SPAC Merger Is Approved
Icelandic Company Set To Go Public Next Week On The Nasdaq
Alvotech will cease to be a privately listed company next week, with its merger with special purpose acquisition company Oaktree Acquisition Corp. II set to close “on or about 15 June.”
You may also be interested in...
Alvotech has begun its fourth biosimilar clinical trial program, announcing the start of studies for its AVT03 proposed denosumab rival to Prolia/Xgeva.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.